Bio-mac – Dr. Wade McKenna

Study on Compensated Rotator Cuff Tear Arthropathy by Orthopedic Surgeon and Stem Cell Specialist, Wade McKenna, DO Published in Techniques in Shoulder and Elbow Surgery

Study on Compensated Rotator Cuff Tear Arthropathy by Orthopedic Surgeon and Stem Cell Specialist, Wade McKenna, DO Published in Techniques in Shoulder and Elbow Surgery

Dallas-Fort Worth, Texas (PRWEB) November 08, 2015

A Study by orthopedic surgeon and stem cell specialist, Dr. Wade McKenna of the Riordan-McKenna Institute entitled, “Outpatient Treatment of Compensated Cuff Arthropathy Using Inlay Arthroplasty With Subscapularis Preservation” is published in the December edition of Techniques in Shoulder and Elbow Surgery.

Picture of Wade McKenna, DO

Dr. McKenna is co-founder and chief medical officer of the Riordan-McKenna Institute of Regenerative Orthopedics (RMI) in Southlake, Texas. Co-author of this work is Troy Chandler, PA-C from North Central Texas Orthopedics in Decatur, Texas.

Rotator cuff tear arthropathy sometimes develops in patients who have had a very large, long-standing rotator cuff injury. In CTA, changes in the shoulder due to the rotator cuff tear cause arthritis and lead to destruction of joint cartilage.

The Shoulder HemiCAP® restoration procedure is designed to match the shape and contour of individual patient’s cartilage and joint surface and be an ideal alternative to shoulder replacement. It simply recreates a smooth surface where the cartilage has worn away — similar to a filling for a tooth cavity.

The study examined a consecutive series of 50 CTA patients treated by Dr. McKenna from 2007 to 2015. It concluded that resurfacing the humeral head (shoulder bone) using a HemiCAP shoulder implant preserves the joint and avoids bone loss and complications associated with more invasive procedures like stemmed arthroplasty or total shoulder replacement.

Furthermore, the HemiCAP procedure disrupts the degenerative cycle of early-stage CTA, effectively addresses causes of pain, and avoids further muscle imbalance. The latter is achieved by a special deltoid muscle-splitting approach that leaves the tendon under the shoulder bone intact.

All of these advantages resulted in accelerated recovery and rehabilitation for patients.

“We are very pleased with the positive outcome of this study. Although we specialize in non-surgical stem cell interventions at RMI, sometimes, as in the case of CTA, surgical intervention is indicated. That’s why it’s important for patients to seek out an experienced orthopedic surgeon who, in addition to orthopedic expertise, is well versed on the latest advances in stem cell therapy. A surgeon needs both to know when stem cell therapy may be effective and when surgery, perhaps augmented with biologics like bone marrow aspirate concentrate (BMAC) and AlphaGEMS amniotic tissue product, is a better option,” commented Dr. McKenna.

About Riordan-McKenna Institute (RMI)

RMI specializes in non-surgical treatment of acute and chronic orthopedic conditions using *AlphaGEMS flowable amniotic tissue allograft and bone marrow aspirate concentrate (BMAC) that is harvested using the patented BioMAC bone marrow aspiration cannula. Common conditions treated include meniscal tears, ACL injuries, rotator cuff injuries, runner’s knee, tennis elbow, and joint pain due to degenerative conditions like osteoarthritis. RMI also uses AlphaPATCH amniotic membranes as part of a complete wound care treatment regimen.

RMI also augments orthopedic surgeries with BMAC and AlphaGEMS to promote better post-surgical outcomes.

BMAC contains a patient’s own mesenchymal stem cells (MSC,) hematopoietic stem cells (CD34+), growth factors and other progenitor cells. AlphaGEMS is composed of collagens and other structural proteins, which provide a biologic matrix that supports angiogenesis, tissue growth and new collagen during tissue regeneration and repair.

*AlphaGEMS and AlphaPATCH products are produced by Amniotic Therapies Inc. from donated amniotic tissue after normal healthy births. For more information about AlphaGEMS, please visit: http://www.rmiclinic.com/non-surgical-stem-cell-injections-joint-pain/stemnexa-protocol/

http://www.rmiclinic.com

801 E. Southlake Blvd.

Southlake, Texas

76092

Tel: (817) 776-8155

Toll Free: (877) 899-7836

Fax: (817) 776-8154

For the original version on PRWeb visit: http://www.prweb.com/releases/2015/11/prweb13068117.htm

UCLA Wide Receiver and Canadian Decathlon Standout Zack Bornstein Bounces Back After Stem Cell Therapy

UCLA Wide Receiver Zack Bornstein
UCLA Wide Receiver Zack Bornstein

UCLA wide receiver and Canadian decathlon standout Zach Bornstein suffered a hamstring tear 18 months ago. Conventional treatment and therapy were not working so Zach decided to undergo stem cell therapy at Riordan-McKenna Institute in late June 2015. Dr. McKenna treated Zack with precisely guided injections of bone marrow aspirate concentrate (BMAC) harvested with the patented BioMAC bone marrow aspiration cannula and *AlphGEMS amniotic tissue product.

Complete healing was confirmed by MRI 8 weeks after treatment:

1) No evidence for hamstring strain or denervation and no evidence for tendon tear.
2) No evidence for focal atrophy or hematoma.
3) No osseous abnormalities seen.

After receiving the MRI results, Zack’s father Dean said, “I am not a doctor but looks like you and your procedure has performed a medical miracle! …Thanks for all of your efforts.”

Zack is currently a red shirt freshman at UCLA. He played football at Oaks Christian High School from 2011-’14 and lettered 3 years in football and all 4 years in track. In 2013, Zack was named to the All-Marmonte 2nd team. He played in the FBU Youth All-American game in 2010. In track, he is considered to be one of the top decathletes in the country. Zack competed at the 2013 Pan American Junior Championships in Medellin, Columbia, finishing in 5th place with 7,097 points. In July of 2013, he became the Canadian Junior National Champion (6,918 pts). Zack won the silver medal at the 2013 Arcadia Invitational Decathlon, scoring 6,967 points to set a new California state record for juniors (2nd highest score in California state history). Zack is a 12-time National Champion, 44-time All-American and a member of three National Championship cross country teams.

*Amniotic tissue is donated after normal, healthy births.

 

Originally posted on RMI.

Biologic Therapies Recieves 510(k) Clearance

Biologic Therapies Receives 510(k) Clearance for Bio-MAC and Bio-CORE Bone Marrow Aspiration Cannulas

Ocala, FL (May 12, 2015) – Biologic Therapies, a medical device company specializing in the design and development of products for regenerative medicine, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Bio-MAC and Bio-CORE cannulas. The Bio-MAC Bone Marrow Aspiration Cannula and Bio-CORE Bone Marrow Biopsy Cannula are minimally invasive devices that are inserted into bone with any standard surgical drill.

5-Bio-MACs-Sizes-Logo                               Bio-MAC-Bio-CORE
                                                                         Bio-MAC Bone Marrow Aspiration Cannulas                             Bio-CORE Bone Marrow Biopsy Cannulas

Dr. Wade McKenna, Biologic Therapies’ Chief Medical Director, said, “Unlike traditional bone marrow aspiration cannulas, which are pounded into bone with a mallet or pushed in with brute force, the power driven Bio-MAC and Bio-CORE do not cause microfractures in the bone that can result in pain for the patient. Plus, the Bio-MAC and Bio-CORE are available in multiple lengths, which allow for fast and easy bone marrow draws throughout the anatomy. In addition to the iliac crest and lumbar vertebral body, the tibia, humerus and calcaneus are now viable sites for bone marrow aspiration.

“Our products enable physicians to aspirate bone marrow in their own office with only local anesthesia, which is revolutionary. The ability to aspirate a patient’s marrow, concentrate the marrow in a centrifuge to derive the maximum number of regenerative cells and growth factors, and then give the concentrated cells and growth factors back to the patient in a physician’s office makes regenerative cell therapy a much easier, more available and less costly procedure. The entire point-of-care procedure takes less than 30 minutes. Of course, the Bio-MAC and Bio-CORE are also used in hospitals and surgery centers.”

Autospin-sm         Autospin-Kit
AUTOSPIN Centrifuge                               AUTOSPIN BMAC Convenience Kit

For concentrating bone marrow Biologic Therapies offers its AUTOSPIN centrifuge and convenience kits. The AUTOSPIN is a fully automated dual spin centrifuge that can be programmed to deliver a volume of 3 to 10 ml from each processing cycle. It is a closed system, which dramatically reduces the chance for contamination. Two separate AUTOSPIN Convenience Kits contain all the components needed to process Bone Marrow Aspirate Concentrate (BMAC) or Platelet-Rich Plasma (PRP).

Luke Whalen, Biologic Therapies’ CEO, said, “My team and I are very pleased to receive 510(k) clearance for our Bio-MAC and Bio-CORE cannulas. We are currently expanding our business throughout the United States, Europe, India, China and South Africa. Biologic Therapies is improving the health of patients around the world by making our products the standard of care for regenerative medicine.”

About Biologic Therapies

Based in Ocala, Florida, Biologic Therapies, Inc. (www.biologictherapies.com) (www.amniotictherapies.com) develops innovative technologies to meet the needs of the emerging regenerative medicine segment of the healthcare market. Biologic Therapies’ mission is to provide groundbreaking medical technologies and procedures that significantly enhance the body’s natural healing ability, thereby providing patients with improved outcomes and quicker restoration of function.